Dr. Freedman has a particular interest in epidemiologic and translational research within pediatric supportive oncology. He aims to advance the understanding and treatment of symptoms, infections, and organ toxicities in pediatric cancer and hematopoietic stem cell transplant patients.
Dr. Kolon is an expert in the care of children with genital disorders and renal/bladder/prostate cancers. His expertise in pediatric urologic oncology includes optimizing organ-sparing surgery and preservation of fertility in oncology patients.
Dr. Fisher's research focuses on infections in children with immunocompromising conditions. He is particularly interested in infections in children with cancer and serves as the chair of the Infectious Disease Domain within the Children’s Oncology Group.
Dr. Goldfarb has special interests in the treatment of children with end-stage lung disease such as cystic fibrosis, interstitial lung disease, pulmonary late effects of oncology treatments, and other pulmonary disorders.
Dr. Rheingold's research interests center on acute lymphocytic leukemia, and she serves on the Children's Oncology Group's Relapsed ALL, Infant ALL, and Complementary Therapies committees. In addition, she is investigates complementary and alternative therapies, supportive care for oncology patients undergoing chemotherapy, medical education, and rare childhood tumors.
Dr. Silber is the director of the Center for Outcomes Research at CHOP, and is an internationally known authority on outcomes measurement and severity adjustment for both adult and pediatric applications.
Dr. Schwartz's research focuses on behavioral and psychosocial aspects of cancer and its treatment in adolescents and young adults (AYAs), a group of patients with unique medical and psychosocial challenges. Most of her current studies aim to understand and improve self-management among AYAs.
Dr. Nissim is a biochemist and a pioneer in the application of stable isotopes, mass spectrometry, and nuclear magnetic resonance to study metabolome and fluxome and their coupling to genome in normal and disease states. His long-standing interest focuses on understanding the cause, mechanisms, and outcome of metabolic disorders.